A venture capital firm with offices in USA and Canada is making investments out of its vintage 2017 fund and is exclusively focused on supporting entrepreneurs commercializing advanced materials and advanced material process innovations within four verticals: energy, electronics, health, and sustainability. The firm typically makes initial investments in the $1M-$4M range and up to $8M over the life of the investment (more or less may be initially invested depending on the deal). The firm prefers to lead deals but will also participate in a syndicate as a co-investor. The firm, with strategic LP relationships in Asia, Europe, the Middle East, and North America invests globally and looks to make 3-4 new investments per year.

Within healthcare, the firm is interested in medical devices and diagnostics whose underlying technology is enabled by advanced materials or advanced material process innovations. The firm has a particular interest in 3D printing and genomics/proteomics R&D applications. The firm does not make investments in pharmaceuticals/therapeutics. Past investments have included a manufacturer of semiconductor radiation detectors enabling a new generation of detection and imaging equipment, a company developing a disruptive 3D bioprinting platform, and a company developing functional surfaces with anti-microbial and anti-fouling properties.

The firm prefers to work with experienced management teams, but is open to working with less experienced entrepreneurs or incomplete management teams given the firm can add value through corporate strategy and operational experience to help accelerate development. The firm prefers to invest in revenue-generating companies but is open to evaluating pre-revenue companies as well. The firm typically seeks a board seat along with investment.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

A cross-border life science investment firm that focuses on the pharmaceutical, medical device, and diagnostics sectors. Currently, the firm has close to $1B AUM. In addition to investing in Chinese and American companies, the firmis actively involved in supporting our portfolio companies through cross-border partnerships. The firm generally makes investments ranging from $5-$30 MM USD.

For pharmaceuticals, the firm looks at assets ranging from Ph I to marketed with a preference towards post-Phase IIb products. For medical device products, the firm looks at a wide variety of products with a preference for technologies that are soon to be market ready. Sector interests include but are not limited to cardiovascular, surgical, ENT, orthopedics, wound care, robotics, and others. For diagnostics, the firm invests in a broad range of technology including POCT, IVD, and molecular diagnostics but also targets non-conventional and invasive diagnostics (such as IVUS/OCT, breath based, GI, etc…). The firm is also interested in revenue generating companies working in the animal health space.

The firm has no specific management team requirements.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

A venture arm of a healthcare distribution and information technology solutions company is a stage-agnostic investor, and makes investments from Series A to growth stage. Investments are therefore varied in size relative to the type of investment; initial allocations are most often from $3-7 million with the possibility of follow-on investments up to $15 million. The firm is open to opportunities worldwide but has previously focused on investing in the USA, Canada and Europe.

The firm focuses on four key areas of innovation in healthcare; alternative care delivery models, consumer health, pharma value chain, and data value chain. The firm invests in technologies at all stages.

The firm has no set requirements for IRR or other metrics, but instead focuses on how a company’s technology fits with the four focus areas of the firm’s investment space, and how the firm can potentially add value to the company.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

A VC firm based in CA invests in companies in Consumer & FinTech, Blockchain, Enterprise & Big Data as well as Life Science & Digital Health. For companies in the life sciences, the firm generally invests in Series A-C rounds, committing between $1-10M in capital. The firm is willing to invest in both the US and China, and will consider companies in pre-clinical and clinical development.

Within the life sciences, the firm is willing to invest in therapeutics, diagnostics, medtech, digital health and R&D services. For therapeutics, the firm will consider traditional therapeutics that are first-in-class, either a novel target or novel therapeutic, but is agnostic to indication. For diagnostics, medtech, digital health and R&D services, the firm focuses on AI-based technologies. Previous investments include AI-based drug discovery platforms, pathology screening, diagnostic services and care management platforms.

The firm looks for companies with a strong management team, large market opportunity and a disruptive technology. When investing, the firm is willing lead or co-invest, and will occasionally take a board seat after investment.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

A private investment firm founded and based in California, USA invests in seed and early-stage health technology companies. The typical investment size for seed investment ranges from $250K to $1M (usually in equity or convertible notes). For early-stage companies, the firm typically co-invests with other VC firms in Seed and Series A financing and the investment size will depend on the company’s financial needs. The firm is geographically agnostic but prefers start-ups to be based on the West Coast. The firm is actively seeking new investment opportunities.

Historically, the firm has invested in technology and life sciences, with notable biotech investments in Amgen and Biogen. Today, the firm has a focus on the digital health and informatics space, but also invests in novel therapeutics. The firm is agnostic in terms of subsectors and indications, including orphan indications. The firm will only consider technologies with proof of concept and strong scientific rationale. Historically, the firm has invested in therapeutics that address oncology, infectious diseases, cardiovascular, and metabolic disorders; drug delivery; orthopedic devices; genomics.

The firm takes a board seat in some cases, and prefers to syndicate on opportunities.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

A newly established venture capital firm is focused on technologies that enhance the human experience and contribute to their well-being. For initial investment, the firm will invest $100-500K and will reserve some funds for follow-on investment. The firm invests mainly in Seed to Series A rounds and often acts as the first institutional investor. Currently, the firm is focused on investing in companies based in the USA, and aims to make 8-10 investments in bio/healthcare technologies.

The firm is interested in companies dedicated to genetics, microbiome, personal pharmaceuticals/diagnostics, VR/AR, consumer-facing medtech or digital health technologies, etc. The firm does not invest in traditional biopharmaceuticals or medical devices, but open to those that require 510k approval.

The firm is open to working with all types of management teams and has no specific management requirements. They could lead the round at seed stage but typically syndicate with other investors for Series A. The firm will take an active role in supporting their companies with needed guidance and resources.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

A VC fund is focused on the earliest stage companies looking to expand to the Chinese market. The firm will invest between $50-250K in companies that are preclinical/in development and looks to be a strategic partner, either by helping the company enter the Chinese market, or find a licensing opportunity with one of the firm’s strategic partners in China. The firm is looking for therapeutic, medical device or diagnostics companies, but will generally not consider digital health companies due to the difficulty in adapting them to the Chinese market. The firm is currently looking to make about 4 investments a year, about 1 per quarter.

The firm is currently focused primarily on medical devices, but will consider therapeutics and diagnostics as well. For medical devices, the firm prefers 510k pathway. The firm is generally agnostic to subsector and indication, but is seeking technologies that are relevant to the Chinese market.

While it is not required, the firm prefers to take a board seat after investing, since they are looking to be active strategic partners in each company in which the firm invests.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.